Table 3.
Treatment-related adverse events (TRAEs) that occurred at any grade in patients treated with mobocertinib (N=16).
| Adverse Events | Grade 1-2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|
| Fatigue | 1 (6%) | 0 | 0 | 0 |
| Nail toxicity | 0 | 0 | 0 | 0 |
| Rash | 2 (12%) | 0 | 0 | 0 |
| Dry skin | 1 (6%) | 0 | 0 | 0 |
| Decrease appetite | 1 (6%) | 0 | 0 | 0 |
| Diarrhea | 6 (38%) | 3 (19%) | 0 | 0 |
| Headache | 0 | 0 | 0 | 0 |
| Pruritis | 1 (6%) | 0 | 0 | 0 |
| Nausea | 3 (19%) | 1 (6%) | 0 | 0 |
| Thrombocytopenia | 0 | 0 | 0 | 0 |
| Leukopenia | 0 | 0 | 0 | 0 |
| Cough | 0 | 0 | 0 | 0 |
| Constipation | 0 | 0 | 0 | 0 |
| Acne | 1 (6%) | 0 | 0 | 0 |
| Anemia | 1 (6%) | 0 | 0 | 0 |
| Stomatitis | 0 | 0 | 0 | 0 |
| Renal Failure | 1 (6%) | 0 | 1 (6%) | 0 |